Drug Discovery & DDS Weekly Report May 24, 2026

Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors

Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies

NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors

BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor

GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation

Incyte Partners with Edison Scientific to Integrate “Kosmos” AI Platform for Enhanced Drug Discovery and Development

GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment

GLP-1 Drug Manufacturing Surges: CDMOs Scale Peptide Synthesis, Driving Technology Transfer